Tempest Therapeutics is a biopharmaceutical company, focused on developing treatments for endocrine diseases. Co.'s three product candidates are: Livoletide (AZP-531), which is for the treatment Prader-Willi syndrome, a genetic endocrine disease usually characterized by hyperphagia, or insatiable hunger; nevanimibe (ATR-101), which is a potential treatment for patients with congenital adrenal hyperplasia, a monogenic adrenal disease that requires lifelong treatment with exogenous cortisol, often at high doses; and NK3R antagonist (MLE-301), which is a potential treatment of vasomotor symptoms commonly known as hot flashes and night sweats, in menopausal women. We show 11 historical shares outstanding datapoints in our coverage of TPST's shares outstanding history.
Understanding the changing numbers of TPST shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like TPST versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching TPST by allowing them to research TPST shares outstanding history
as well as any other stock in our coverage universe. |
Free TPST Email Alerts:
Video: Shares Outstanding Importance
